Arrowhead Pharmaceuticals, Inc. is a biotech company developing new medicines.
Arrowhead Pharmaceuticals, Inc. (ARWR) is expected to report earnings on Tuesday, November 24, 2026, after the close. Estimated release time 16:06 ET. Consensus EPS estimate is $-1.59.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | FY2026 Q2 | $-1.28 | $-1.36 | -6.3% | $75.25M |
| 2026-05-07 | FY2026 Q1 | $-1.09 | $-0.93 | +14.7% | $73.74M |
| 2026-02-05 | FY2025 Q4 | $0.60 | $0.22 | -63.3% | $264.03M |
| 2025-11-25 | FY2025 Q3 | $-0.11 | $-0.17 | -52.4% | $256.47M |
| 2025-02-10 | FY2024 Q4 | $-0.42 | $-1.39 | -231.0% | $2.50M |
| 2024-08-08 | FY2024 Q2 | $-0.58 | $-1.38 | -137.9% | $0 |
| 2024-05-09 | FY2024 Q1 | $-0.06 | $-1.02 | -1600.0% | $0 |
| 2024-02-06 | FY2023 Q4 | $-0.78 | $-1.24 | -59.0% | $3.55M |
ARWR has beaten consensus EPS in 1 of its last 8 reported quarters.
Highlights from ARWR's Aug 4 report: EPS of -$1.36 — a miss vs the -$1.28 estimate (-6%); revenue of $75M — a big beat vs the $44M consensus (+70%).
See ARWR on the live calendar →